INTRODUCTION
Psoriasis is a chronic relapsing immune-mediated disease affecting
around 125 million people worldwide.1Plaque psoriasis
is the commonest variant that accounts for 90% of psoriasis
cases.2 Clinically, Plaque psoriasis is characterized
by sharply demarcated red, scaly lesions with desquamation.1With the further understanding of the pathogenesis of
psoriasis, targeted biologics are more and more widely used as
first-line agents in the treatment of moderate and severe psoriasis, and
play a positive role in the treatment of refractory and special types of
psoriasis. 3 4Howeve,topical
medications is still the most commonly used treatment for mild to
moderate psoriasis and all patients can benefit from extensive
application of emollients.3,5Up to now,only a few
meta-analysis studies have compared the efficacy of different topical
therapies for plaque
psoriasis.6-10To
date, a large number of randomized controlled trials have studied the
efficacy and safety of some novel topical drugs,such as aryl hydrocarbon
receptor (AhR) inhibitors(tapinarof, benvitimod), phosphodiesterase type
4 (PDE-4) inhibitors(roflumilast) and janus kinase-signal transducer and
activator of transcription(JAK-STAT) Inhibitors(tofacitinib,
ruxolitinib) and proformed better efficacy.
For completeness,we report an
overview of all randomized controlled trials of 10 topical medicine for
the treatment of plaque psoriasis and updated the NMA and based
on hierarchical cluster analyses to
evaluate the short-term topical
teatment efficacy,safety and
tolerability. It is hoped that,
to some extent,these results can provide information for doctors when
choosing therapeutic in clinic.